Hematologic Oncology

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses considerations for treatment strategies in patients with chronic lymphocytic leukemia.

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Adding daratumumab to lenalidomide and dexamethasone reduced the risk of disease progression or death by 45% compared with lenalidomide/dexamethasone alone in newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the data behind the frontline approval of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) in multiple myeloma.

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses allogeneic stem cell transplant (ASCT) in the treatment of patients with acute myeloid leukemia (AML).

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses transplant and maintenance for the treatment of patients with high-risk multiple myeloma.

Neil P. Shah, MD, PhD, discusses emerging agents and the tyrosine kinase inhibitor discontinuation approach in the landscape of chronic myeloid leukemia.

The FDA has granted a priority review designation to a supplemental new drug application for ruxolitinib (Jakafi) for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids.

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

Nancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.

Hetty Carraway, MD, highlights ongoing genomic research in acute myeloid leukemia, as well as recent therapeutic advances in the field.

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

Vivian G. Oehler, MD, discusses the diagnosis, risk prognostication and therapeutic strategies for polycythemia vera, essential thrombocytopenia, and myelofibrosis.

A new drug application has been submitted to Japan's Ministry of Health, Labor and Welfare for quizartinib for the treatment of adult patients with FLT3-ITD–positive acute myeloid leukemia.

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses drug development in acute myeloid leukemia (AML).

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Mary-Beth Percival, MD, discusses the ongoing development of FLT3 inhibitors and other current research in patients with AML.

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).

Aaron Gerds, MD, discusses the activity and drawbacks with current systemic agents in myeloproliferative neoplasms.

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.